Comparative Pharmacology
Head-to-head clinical analysis: BUSPIRONE HYDROCHLORIDE versus MILTOWN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSPIRONE HYDROCHLORIDE versus MILTOWN.
BUSPIRONE HYDROCHLORIDE vs MILTOWN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at serotonin 5-HT1A receptors, primarily in the raphe nuclei and hippocampus; also exhibits antagonist properties at presynaptic 5-HT1A autoreceptors and postsynaptic 5-HT1A receptors, resulting in decreased serotonergic activity. Additionally, it has moderate affinity for dopamine D2 receptors (antagonist) and alpha2-adrenergic receptors.
Miltown (meprobamate) is a carbamate derivative that acts as a central nervous system depressant. Its mechanism of action is not fully understood, but it is believed to exert its effects by modulating GABAergic neurotransmission, possibly by binding to GABA receptors and enhancing inhibitory neurotransmission. It also has sedative, anxiolytic, and muscle relaxant properties.
Initial dose: 7.5 mg orally twice daily; may increase by 2.5-5 mg every 2-3 days to a target dose of 15-30 mg/day in divided doses (2-3 times daily). Maximum dose: 60 mg/day divided twice daily.
400 mg orally 3-4 times daily; maximum 2400 mg/day.
None Documented
None Documented
2-3 hours terminal half-life; clinical context: requires multiple daily dosing (3 times daily) due to short half-life; no active metabolites prolonging effect.
10 hours (range 6-17 hours); prolonged in hepatic or renal impairment.
Renal: 29-63% (as metabolites; <1% unchanged); Fecal: 18-38%; Hepatic metabolism primarily via CYP3A4; total clearance 1.5-3.5 L/h/kg.
Primarily renal, with 10-20% excreted unchanged; remainder as inactive metabolites (e.g., hydroxymeprobamate). Less than 2% fecal.
Category A/B
Category C
Anxiolytic
Anxiolytic